Abstract 4552: Preclinical characterization of BMS-986218, a novel nonfucosylated anti–CTLA-4 antibody designed to enhance antitumor activity
John Engelhardt(Bristol-Myers Squibb (United States)), Karen Price(Purchase College), Natalie Bezman(University of California, San Francisco), Paula So(Bristol-Myers Squibb (United States)), John T. Loffredo(Bristol-Myers Squibb (United States)), Rahima Akter(Bristol-Myers Squibb (United States))
Cited by 11
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
|Journal of Clinical Investigation|2020|133
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96